0.5229

3.26% 0.0165

After Hours: .53 0.0071 +1.36%

Context Therapeutics Inc (CNTX)

Overview News Price History Financials Discussions Forecast

Context Therapeutics Inc stock is traded at $0.5229, with a volume of 1.26M. It is up +3.26% in the last 24 hours and down -16.05% over the past month. Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Previous Close:

$0.5064

Open:

$0.4978

24h Volume:

1.26M

Relative Volume:

0.52

Market Cap:

$48.04M

Revenue:

Net Income/Loss:

$-40.23M

P/E Ratio:

-1.2232

EPS:

-0.4275

Net Cash Flow:

$-34.82M

1W Performance:

+8.04%

1M Performance:

-16.05%

6M Performance:

-77.27%

1Y Performance:

-28.98%

1-Day Range:

$0.49

$0.535

1-Week Range:

$0.432

$0.535

52-Week Range:

$0.432

$3.62

Context Therapeutics Inc Stock (CNTX) Company Profile

Name

Context Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

267-225-7416

Address

2001 MARKET STREET, PHILADELPHIA

Employee

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

CNTX's Discussions on Twitter

Compare CNTX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CNTX Context Therapeutics Inc	0.5229	43.17M	0	-40.23M	-34.82M	-0.4275
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-18-25	Initiated	Guggenheim	Buy
Apr-21-25	Initiated	William Blair	Outperform
Jan-08-25	Initiated	JMP Securities	Mkt Outperform
Nov-25-24	Initiated	D. Boral Capital	Buy
May-16-24	Initiated	Piper Sandler	Overweight

Context Therapeutics Inc Stock (CNTX) Latest News

Aug 15, 2026

CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Stocktwits

Aug 15, 2026

Aug 14, 2026

MPM BioImpact reports 1.4% stake in Context Therapeutics (CNTX) common stock - Stock Titan

Aug 14, 2026

Aug 12, 2026

Blue Owl Capital Holdings (CNTX) reports 3.19% beneficial stake in Context Therapeutics - Stock Titan

Aug 12, 2026

Context Therapeutics Narrows Pipeline as Quarterly Loss Widens - MyChesCo

Aug 12, 2026

Aug 11, 2026

Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4 - moomoo.com

Aug 11, 2026

Aug 10, 2026

Enterprise value to EBITDA forward of Context Therapeutics, Inc. – FWB:6K9 - TradingView

Aug 10, 2026

Aug 07, 2026

LifeSci Capital downgrades Context Therapeutics (CNTX) to a Hold - The Globe and Mail

Aug 07, 2026